Home News Page 4

News

First Patients Dosed in Phase II Trial with Trastuzumab Duocarmazine in HER2-expressing Endometrial Carcinoma

A first patient has started treatment in a Phase II study designed to evaluate the safety and efficacy of...

Advisory Committee Votes in Favor of Positive Benefit/Risk Profile for Belantamab Mafodotin in R/R...

The U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) has voted 12-0 in favor of positive...

Immunomedics and Roche Expand Study Collaboration in First-line Metastatic Triple-negative Breast Cancer

Immunomedics and Roche have agreed to expand their clinical trial collaboration to evaluate sacituzumab govitecan-hziy (Trodelvy™), a Trop-2-directed antibody...

Revitope and Junshi Biosciences Sign Research Collaboration to Develop Next Generation Immunotherapies

Cambridge (MA) based Revitope Oncology, a biotechnology company advancing a new class of precision cancer immunotherapies, and Junshi Biosciences,...
Featured Image Courtesy: Byondis Biopharmaceuticals (previously Synthon Biopharmaceuticals, Nijmegen, The Netherlands.

Trastuzumab Duocarmazine Selected to be part of a New Investigational Treatment Arm for the...

The Quantum Leap Healthcare Collaborative™, a 501c(3) charitable organization established as a collaboration between medical researchers at University of...

U.S. Patent for Bolt Biotherapeutics’ Boltbody™ ISAC Platform Technology is a Major Milestone in...

San Francisco Bay Area-based Bolt Biotherapeutics confirmed that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent...

Rakuten Medical and Merck KGaA sign Multi-year Agreement for ASP-1929

Rakuten Medical and Merck KGaA, Darmstadt, Germany have signed a multi-year agreement under which Merck provides cetuximab to Rakuten...

FDA Lifts Partial Clinical Hold on Pivotal Phase II Clinical Trial of Camidanlumab Tesirine

Earlier this week the U.S. Food and Drug Administration (FDA) lifted a partial clinical hold on the pivotal Phase...

HER2-targeting Trastuzumab Deruxtecan Shows Promise in Patients with Non-breast/Gastric Cancers

Results from a phase I study investigating fam-trastuzumab deruxtecan-nxki (formerly known as DS-8201a; Enhertu®; Daiichi Sankyo and AstraZeneca) showed...
New York Stock Exchange (released under Public Domain license. Photo courtesy 2020 Jean Beaufort.

ADC Therapeutics Completes U.S. $ 267 Million Initial Public Offering

Earlier today, New Ventures Funds, a venture fund targeting investments in companies across healthcare and life sciences, confirmed that...